UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): July 16, 2008
GTC BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
| | | | |
| Massachusetts | | 0-21794 | | 04-3186494 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
|
175 CROSSING BOULEVARD FRAMINGHAM, MASSACHUSETTS 01702 |
| (Address of Principal Executive Offices) (Zip Code) |
(508) 620-9700
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On July 16, 2008, we received a notice from The Nasdaq Stock Market that we have failed to regain compliance with the minimum $1.00 bid price requirement for continued listing on the Nasdaq Global Market, as specified by Marketplace Rule
4450(a)(5), during the 180 day compliance period afforded to us by Marketplace Rule 4450(e)(2). On July 18, 2008, we issued a press release announcing our receipt of the notice. A copy of the press release is filed with this Current Report as Exhibit 99.1 and is incorporated herein by this reference.
| Item 9.01 | Financial Statements and Exhibits. |
| | |
| 99.1 | | Press Release of GTC Biotherapeutics, Inc., dated July 18, 2008, reporting GTC’s receipt of Nasdaq notice dated July 16, 2008. Filed herewith. |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | GTC BIOTHERAPEUTICS, INC. |
| | |
Dated: July 21, 2008 | | By: | | /s/ John B. Green |
| | | | John B. Green |
| | | | Senior Vice President, Treasurer and Chief Financial Officer |
-3-
EXHIBIT INDEX
| | |
Exhibit No. | | Description |
| 99.1 | | Press Release of GTC Biotherapeutics, Inc., dated July 18, 2008, reporting GTC’s receipt of Nasdaq notice dated July 16, 2008. Filed herewith. |
